Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue 1.4 Market Analysis by Type 1.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Riluzole 1.4.3 Edaravone (Radicava) 1.4.4 Other 1.5 Market by Application 1.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application: 2020 VS 2026 1.5.2 Hospital 1.5.3 Drugs Store 1.5.4 Other 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Perspective (2015-2026) 2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Growth Trends by Regions 2.2.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Share by Regions (2015-2020) 2.2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Strategy 2.3.6 Primary Interviews with Key Amyotrophic Lateral Sclerosis (ALS) Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Market Size 3.1.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue (2015-2020) 3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Players (2015-2020) 3.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Concentration Ratio 3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in 2019 3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players Head office and Area Served 3.4 Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Product Solution and Service 3.5 Date of Enter into Amyotrophic Lateral Sclerosis (ALS) Treatment Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Type (2015-2020) 4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Type (2021-2026) 5 Amyotrophic Lateral Sclerosis (ALS) Treatment Breakdown Data by Application (2015-2026) 5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2015-2020) 6.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in North America (2019-2020) 6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) 6.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) 7 Europe 7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2015-2020) 7.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in Europe (2019-2020) 7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) 7.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) 8 China 8.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2015-2020) 8.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in China (2019-2020) 8.3 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) 8.4 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) 9 Japan 9.1 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2015-2020) 9.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in Japan (2019-2020) 9.3 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) 9.4 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2015-2020) 10.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) 10.4 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) 11 India 11.1 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2015-2020) 11.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in India (2019-2020) 11.3 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) 11.4 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2015-2020) 12.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in Central & South America (2019-2020) 12.3 Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) 12.4 Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) 13Key Players Profiles 13.1 Mitsubishi Tanabe Pharma 13.1.1 Mitsubishi Tanabe Pharma Company Details 13.1.2 Mitsubishi Tanabe Pharma Business Overview and Its Total Revenue 13.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction 13.1.4 Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020)) 13.1.5 Mitsubishi Tanabe Pharma Recent Development 13.2 Sanofi 13.2.1 Sanofi Company Details 13.2.2 Sanofi Business Overview and Its Total Revenue 13.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction 13.2.4 Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) 13.2.5 Sanofi Recent Development 13.3 Mylan Pharma 13.3.1 Mylan Pharma Company Details 13.3.2 Mylan Pharma Business Overview and Its Total Revenue 13.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction 13.3.4 Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) 13.3.5 Mylan Pharma Recent Development 13.4 Apotex 13.4.1 Apotex Company Details 13.4.2 Apotex Business Overview and Its Total Revenue 13.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction 13.4.4 Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) 13.4.5 Apotex Recent Development 13.5 Glemark Generics 13.5.1 Glemark Generics Company Details 13.5.2 Glemark Generics Business Overview and Its Total Revenue 13.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction 13.5.4 Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) 13.5.5 Glemark Generics Recent Development 13.6 Covis Pharma 13.6.1 Covis Pharma Company Details 13.6.2 Covis Pharma Business Overview and Its Total Revenue 13.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction 13.6.4 Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) 13.6.5 Covis Pharma Recent Development 13.7 Sun Pharma 13.7.1 Sun Pharma Company Details 13.7.2 Sun Pharma Business Overview and Its Total Revenue 13.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction 13.7.4 Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) 13.7.5 Sun Pharma Recent Development 13.8 Lunan Pharma 13.8.1 Lunan Pharma Company Details 13.8.2 Lunan Pharma Business Overview and Its Total Revenue 13.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction 13.8.4 Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) 13.8.5 Lunan Pharma Recent Development 14Analyst's Viewpoints/Conclusions 15Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. Amyotrophic Lateral Sclerosis (ALS) Treatment Key Market Segments Table 2. Key Players Covered: Ranking by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Table 3. Ranking of Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Riluzole Table 6. Key Players of Edaravone (Radicava) Table 7. Key Players of Other Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions (US$ Million): 2020 VS 2026 Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions (2015-2020) (US$ Million) Table 11. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Regions (2015-2020) Table 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Regions (2021-2026) Table 14. Market Top Trends Table 15. Key Drivers: Impact Analysis Table 16. Key Challenges Table 17. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Strategy Table 18. Main Points Interviewed from Key Amyotrophic Lateral Sclerosis (ALS) Treatment Players Table 19. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Players (2015-2020) (Million US$) Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Players (2015-2020) Table 21. Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment as of 2019) Table 22. Global Amyotrophic Lateral Sclerosis (ALS) Treatment by Players Market Concentration Ratio (CR5 and HHI) Table 23. Key Players Headquarters and Area Served Table 24. Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Product Solution and Service Table 25. Date of Enter into Amyotrophic Lateral Sclerosis (ALS) Treatment Market Table 26. Mergers & Acquisitions, Expansion Plans Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) (Million US$) Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Type (2015-2020) Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Application (2015-2020) Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) (Million US$) Table 32. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Application (2021-2026) Table 33. North America Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2019-2020) (Million US$) Table 34. North America Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share (2019-2020) Table 35. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) (Million US$) Table 36. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2015-2020) Table 37. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) (Million US$) Table 38. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2015-2020) Table 39. Europe Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2019-2020) (Million US$) Table 40. Europe Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share (2019-2020) Table 41. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) (Million US$) Table 42. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2015-2020) Table 43. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) (Million US$) Table 44. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2015-2020) Table 45. China Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2019-2020) (Million US$) Table 46. China Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share (2019-2020) Table 47. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) (Million US$) Table 48. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2015-2020) Table 49. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) (Million US$) Table 50. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2015-2020) Table 51. Japan Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2019-2020) (Million US$) Table 52. Japan Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share (2019-2020) Table 53. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) (Million US$) Table 54. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2015-2020) Table 55. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) (Million US$) Table 56. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2015-2020) Table 57. Southeast Asia Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2019-2020) (Million US$) Table 58. Southeast Asia Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share (2019-2020) Table 59. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) (Million US$) Table 60. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2015-2020) Table 61. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) (Million US$) Table 62. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2015-2020) Table 63. India Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2019-2020) (Million US$) Table 64. India Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share (2019-2020) Table 65. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) (Million US$) Table 66. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2015-2020) Table 67. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) (Million US$) Table 68. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2015-2020) Table 69. Central & South America Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2019-2020) (Million US$) Table 70. Central & South America Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share (2019-2020) Table 71. Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2015-2020) (Million US$) Table 72. Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2015-2020) Table 73. Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2015-2020) (Million US$) Table 74. Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2015-2020) Table 75. Mitsubishi Tanabe Pharma Company Details Table 76. Mitsubishi Tanabe Pharma Business Overview Table 77. Mitsubishi Tanabe Pharma Product Table 78. Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) (Million US$) Table 79. Mitsubishi Tanabe Pharma Recent Development Table 80. Sanofi Company Details Table 81. Sanofi Business Overview Table 82. Sanofi Product Table 83. Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) (Million US$) Table 84. Sanofi Recent Development Table 85. Mylan Pharma Company Details Table 86. Mylan Pharma Business Overview Table 87. Mylan Pharma Product Table 88. Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) (Million US$) Table 89. Mylan Pharma Recent Development Table 90. Apotex Company Details Table 91. Apotex Business Overview Table 92. Apotex Product Table 93. Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) (Million US$) Table 94. Apotex Recent Development Table 95. Glemark Generics Company Details Table 96. Glemark Generics Business Overview Table 97. Glemark Generics Product Table 98. Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) (Million US$) Table 99. Glemark Generics Recent Development Table 100. Covis Pharma Company Details Table 101. Covis Pharma Business Overview Table 102. Covis Pharma Product Table 103. Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) (Million US$) Table 104. Covis Pharma Recent Development Table 105. Sun Pharma Company Details Table 106. Sun Pharma Business Overview Table 107. Sun Pharma Product Table 108. Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) (Million US$) Table 109. Sun Pharma Recent Development Table 110. Lunan Pharma Business Overview Table 111. Lunan Pharma Product Table 112. Lunan Pharma Company Details Table 113. Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) (Million US$) Table 114. Lunan Pharma Recent Development Table 115. Research Programs/Design for This Report Table 116. Key Data Information from Secondary Sources Table 117. Key Data Information from Primary Sources List of Figures Figure 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type: 2020 VS 2026 Figure 2. Riluzole Features Figure 3. Edaravone (Radicava) Features Figure 4. Other Features Figure 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application: 2020 VS 2026 Figure 6. Hospital Case Studies Figure 7. Drugs Store Case Studies Figure 8. Other Case Studies Figure 9. Amyotrophic Lateral Sclerosis (ALS) Treatment Report Years Considered Figure 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth 2015-2026 (US$ Million) Figure 11. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Regions: 2020 VS 2026 Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Regions (2021-2026) Figure 13. Porter's Five Forces Analysis Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Players in 2019 Figure 15. Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment as of 2019 Figure 16. The Top 10 and 5 Players Market Share by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in 2019 Figure 17. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 18. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 19. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 20. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 21. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 22. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 23. Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 24. Mitsubishi Tanabe Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 25. Mitsubishi Tanabe Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) Figure 26. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018 Figure 27. Sanofi Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) Figure 28. Mylan Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 29. Mylan Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) Figure 30. Apotex Total Revenue (US$ Million): 2019 Compared with 2018 Figure 31. Apotex Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) Figure 32. Glemark Generics Total Revenue (US$ Million): 2019 Compared with 2018 Figure 33. Glemark Generics Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) Figure 34. Covis Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 35. Covis Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) Figure 36. Sun Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 37. Sun Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) Figure 38. Lunan Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 39. Lunan Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2015-2020) Figure 40. Bottom-up and Top-down Approaches for This Report Figure 41. Data Triangulation Figure 42. Key Executives Interviewed

Mitsubishi Tanabe Pharma Sanofi Mylan Pharma Apotex Glemark Generics Covis Pharma Sun Pharma Lunan Pharma